EGF enema and EGFR monoclonal antibody injection alleviate the inflammatory bowel disease in AMO/DSS induced mice model

[1] Vaughn BP. A practical guide to therapeutic drug monitoring of biologic medications for inflammatory bowel disease. J Clin Med. 2021;10(21). VaughnBP A practical guide to therapeutic drug monitoring of biologic medications for inflammatory bowel disease J Clin Med 2021 10 21 Search in Google Scholar

[2] Cai Z, Wang S, Li J. Treatment of inflammatory bowel disease: A comprehensive review. Front Med (Lausanne). 2021;8:765474. CaiZ WangS LiJ Treatment of inflammatory bowel disease: A comprehensive review Front Med (Lausanne). 2021 8 765474 Search in Google Scholar

[3] Zhang YZ, Li YY. Inflammatory bowel disease: pathogenesis. World J Gastroenterol. 2014;20(1):91–9. ZhangYZ LiYY Inflammatory bowel disease: pathogenesis World J Gastroenterol 2014 20 1 91 9 Search in Google Scholar

[4] Kim ER, Chang DK. Colorectal cancer in inflammatory bowel disease: the risk, pathogenesis, prevention and diagnosis. World J Gastroenterol. 2014;20(29):9872–81. KimER ChangDK Colorectal cancer in inflammatory bowel disease: the risk, pathogenesis, prevention and diagnosis World J Gastroenterol 2014 20 29 9872 81 Search in Google Scholar

[5] Kaser A. Metabolism - new therapeutic targets for inflammatory bowel disease. Drug Res (Stuttg). 2021;71(S 01):S11–S2. KaserA Metabolism - new therapeutic targets for inflammatory bowel disease Drug Res (Stuttg) 2021 71 S 01 S11 S2 Search in Google Scholar

[6] Porter RJ, Arends MJ, Churchhouse AMD, Din S. Inflammatory bowel disease-associated colorectal cancer: Translational risks from mechanisms to medicines. J Crohns Colitis. 2021;15(12):2131–41. PorterRJ ArendsMJ ChurchhouseAMD DinS Inflammatory bowel disease-associated colorectal cancer: Translational risks from mechanisms to medicines J Crohns Colitis 2021 15 12 2131 41 Search in Google Scholar

[7] Axelrad JE, Lichtiger S, Yajnik V. Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment. World J Gastroenterol. 2016;22(20):4794–801. AxelradJE LichtigerS YajnikV Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment World J Gastroenterol 2016 22 20 4794 801 Search in Google Scholar

[8] Liu CY, Cham CM, Chang EB. Epithelial wound healing in inflammatory bowel diseases: the next therapeutic frontier. Transl Res. 2021;236:35–51. LiuCY ChamCM ChangEB Epithelial wound healing in inflammatory bowel diseases: the next therapeutic frontier Transl Res. 2021 236 35 51 Search in Google Scholar

[9] Wee P, Wang Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers (Basel). 2017;9(5). WeeP WangZ Epidermal growth factor receptor cell proliferation signaling pathways Cancers (Basel) 2017 9 5 Search in Google Scholar

[10] Zhao J, Guo M, Yan Y, Wang Y, Zhao X, Yang J, Chen J, Chen C, Tang L, Zeng W, et,al. The miR-7/EGFR axis controls the epithelial cell immunomodulation and regeneration and orchestrates the pathology in inflammatory bowel disease. J Adv Res. 2024;57:119–34. ZhaoJ GuoM YanY WangY ZhaoX YangJ ChenJ ChenC TangL ZengW The miR-7/EGFR axis controls the epithelial cell immunomodulation and regeneration and orchestrates the pathology in inflammatory bowel disease J Adv Res. 2024 57 119 34 Search in Google Scholar

[11] Sipos F, Molnar B, Zagoni T, Berczi L, Tulassay Z. Growth in epithelial cell proliferation and apoptosis correlates specifically to the inflammation activity of inflammatory bowel diseases: Ulcerative colitis shows specific p53- and EGFR expression alterations. Dis Colon Rectum. 2005;48(4):775–86. SiposF MolnarB ZagoniT BercziL TulassayZ Growth in epithelial cell proliferation and apoptosis correlates specifically to the inflammation activity of inflammatory bowel diseases: Ulcerative colitis shows specific p53- and EGFR expression alterations Dis Colon Rectum 2005 48 4 775 86 Search in Google Scholar

[12] Kim TY, Han DS, Eun CS, Chung YW. Recombinant human epidermal growth factor enhances wound healing of pyoderma gangrenosum in a patient with ulcerative colitis. Inflamm Bowel Dis. 2008;14(5):725–7. KimTY HanDS EunCS ChungYW Recombinant human epidermal growth factor enhances wound healing of pyoderma gangrenosum in a patient with ulcerative colitis Inflamm Bowel Dis 2008 14 5 725 7 Search in Google Scholar

[13] McCole DF, Rogler G, Varki N, Barrett KE. Epidermal growth factor partially restores colonic ion transport responses in mouse models of chronic colitis. Gastroenterology. 2005;129(2):591–608. McColeDF RoglerG VarkiN BarrettKE Epidermal growth factor partially restores colonic ion transport responses in mouse models of chronic colitis Gastroenterology 2005 129 2 591 608 Search in Google Scholar

[14] Sinha A, Nightingale J, West KP, Berlanga-Acosta J, Playford RJ. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med. 2003;349(4):350–7. SinhaA NightingaleJ WestKP Berlanga-AcostaJ PlayfordRJ Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis N Engl J Med 2003 349 4 350 7 Search in Google Scholar

[15] Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer. Mol Oncol. 2018;12(1):3–20. SigismundS AvanzatoD LanzettiL Emerging functions of the EGFR in cancer Mol Oncol 2018 12 1 3 20 Search in Google Scholar

[16] Miller I, Min M, Yang C, Tian C, Gookin S, Carter D, Spencer SL. Ki67 is a graded rather than a binary marker of proliferation versus quiescence. Cell Rep. 2018;24(5):1105–12.e5. MillerI MinM YangC TianC GookinS CarterD SpencerSL Ki67 is a graded rather than a binary marker of proliferation versus quiescence Cell Rep 2018 24 5 1105 12.e5 Search in Google Scholar

[17] Setia S, Nehru B, Sanyal SN. Upregulation of MAPK/Erk and PI3K/Akt pathways in ulcerative colitis-associated colon cancer. Biomed Pharmacother. 2014;68(8):1023–9. SetiaS NehruB SanyalSN Upregulation of MAPK/Erk and PI3K/Akt pathways in ulcerative colitis-associated colon cancer Biomed Pharmacother 2014 68 8 1023 9 Search in Google Scholar

[18] Temby M, Boye TL, Hoang J, Nielsen OH. Kinase signaling in colitis-associated colon cancer and inflammatory bowel disease. Biomolecules. 2023;13(11). TembyM BoyeTL HoangJ NielsenOH Kinase signaling in colitis-associated colon cancer and inflammatory bowel disease Biomolecules 2023 13 11 Search in Google Scholar

[19] Li J, Ji Y, Chen N, Dai L, Deng H. Colitis-associated carcinogenesis: crosstalk between tumors, immune cells and gut microbiota. Cell Biosci. 2023;13(1):194. LiJ JiY ChenN DaiL DengH Colitis-associated carcinogenesis: crosstalk between tumors, immune cells and gut microbiota Cell Biosci 2023 13 1 194 Search in Google Scholar

[20] De Robertis M, Massi E, Poeta ML, Carotti S, Morini S, Cecchetelli L, Signori E, Michele Fazio V. The AOM/DSS murine model for the study of colon carcinogenesis: From pathways to diagnosis and therapy studies. J Carcinog. 2011;10:9. De RobertisM MassiE PoetaML CarottiS MoriniS CecchetelliL SignoriE Michele FazioV The AOM/DSS murine model for the study of colon carcinogenesis: From pathways to diagnosis and therapy studies J Carcinog. 2011 10 9 Search in Google Scholar

[21] Kumawat AK, Strid H, Elgbratt K, Tysk C, Bohr J, Hultgren Hörnquist E. Microscopic colitis patients have increased proportions of Ki67(+) proliferating and CD45RO(+) active/memory CD8(+) and CD4(+)8(+) mucosal T cells. J Crohns Colitis. 2013;7(9):694–705. KumawatAK StridH ElgbrattK TyskC BohrJ Hultgren HörnquistE Microscopic colitis patients have increased proportions of Ki67(+) proliferating and CD45RO(+) active/memory CD8(+) and CD4(+)8(+) mucosal T cells J Crohns Colitis 2013 7 9 694 705 Search in Google Scholar

[22] Sjöqvist U, Ost A, Löfberg R. Increased expression of proliferative Ki-67 nuclear antigen is correlated with dysplastic colorectal epithelium in ulcerative colitis. Int J Colorectal Dis. 1999;14(2):107–13. SjöqvistU OstA LöfbergR Increased expression of proliferative Ki-67 nuclear antigen is correlated with dysplastic colorectal epithelium in ulcerative colitis Int J Colorectal Dis 1999 14 2 107 13 Search in Google Scholar

[23] Janani B, Vijayakumar M, Priya K, Kim JH. EGFR-based targeted therapy for colorectal cancer-promises and challenges. Vaccines (Basel). 2022;10(4). JananiB VijayakumarM PriyaK KimJH EGFR-based targeted therapy for colorectal cancer-promises and challenges Vaccines (Basel) 2022 10 4 Search in Google Scholar